KPIs & Operating Metrics(New)
Growth Metrics

AbbVie (ABBV) Accounts Payables (2016 - 2026)

AbbVie has reported Accounts Payables over the past 14 years, most recently at $34.7 billion for Q4 2025.

  • Quarterly Accounts Payables rose 8.73% to $34.7 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $34.7 billion through Dec 2025, up 8.73% year-over-year, with the annual reading at $34.7 billion for FY2025, 8.73% up from the prior year.
  • Accounts Payables was $34.7 billion for Q4 2025 at AbbVie, up from $33.6 billion in the prior quarter.
  • Over five years, Accounts Payables peaked at $34.7 billion in Q4 2025 and troughed at $20.6 billion in Q1 2021.
  • The 5-year median for Accounts Payables is $28.2 billion (2023), against an average of $27.3 billion.
  • Year-over-year, Accounts Payables soared 62.12% in 2021 and then decreased 0.91% in 2025.
  • A 5-year view of Accounts Payables shows it stood at $22.7 billion in 2021, then increased by 11.91% to $25.4 billion in 2022, then increased by 20.66% to $30.6 billion in 2023, then increased by 4.23% to $31.9 billion in 2024, then increased by 8.73% to $34.7 billion in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Accounts Payables are $34.7 billion (Q4 2025), $33.6 billion (Q3 2025), and $32.2 billion (Q2 2025).